Cargando…
A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma
INTRODUCTION: CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. PATIENT CONCERNS: We treated a patient with PC-ALCL that...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104231/ https://www.ncbi.nlm.nih.gov/pubmed/33950967 http://dx.doi.org/10.1097/MD.0000000000025770 |
_version_ | 1783689450343104512 |
---|---|
author | Lyu, Wen-Tian Song, Qi-Bin Qiong, Wang Liu, Jing Yong, Ren Yi, Feng-Tao Han, Dong-liang |
author_facet | Lyu, Wen-Tian Song, Qi-Bin Qiong, Wang Liu, Jing Yong, Ren Yi, Feng-Tao Han, Dong-liang |
author_sort | Lyu, Wen-Tian |
collection | PubMed |
description | INTRODUCTION: CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. PATIENT CONCERNS: We treated a patient with PC-ALCL that exhibited indolent behavior in the past 2 years and aggressive behavior within the last 3 months before presentation. DIAGNOSIS: Aggressive CD30+ primary cutaneous anaplastic large cell lymphoma. INTERVENTIONS: The radiotherapy regimen was individualized in terms of the target volume delineation and dose prescription, and the dose–response relationship was evaluated. OUTCOMES: The mean distance of microscopic infiltration was 14.1 mm in depth and 14.3 mm circumferentially. The lesion completely regressed after the delivery of 40 Gy in 20 fractions over 4 weeks. The tumor did not recur over the next year. CONCLUSION: An aggressive disease course is rare for indolent CD30+ PC-ALCL, which has similar histopathological characteristics as indolent PC-ALCL. The radiotherapy strategy should be individualized with curative intent. |
format | Online Article Text |
id | pubmed-8104231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-81042312021-05-10 A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma Lyu, Wen-Tian Song, Qi-Bin Qiong, Wang Liu, Jing Yong, Ren Yi, Feng-Tao Han, Dong-liang Medicine (Baltimore) 5700 INTRODUCTION: CD30+ primary cutaneous anaplastic large cell lymphoma (PC-ALCL) is a rare T-cell neoplasm, and has been reported to present with an indolent behavior. The PC-ALCL with aggressive behavior has not been reported in the literature. PATIENT CONCERNS: We treated a patient with PC-ALCL that exhibited indolent behavior in the past 2 years and aggressive behavior within the last 3 months before presentation. DIAGNOSIS: Aggressive CD30+ primary cutaneous anaplastic large cell lymphoma. INTERVENTIONS: The radiotherapy regimen was individualized in terms of the target volume delineation and dose prescription, and the dose–response relationship was evaluated. OUTCOMES: The mean distance of microscopic infiltration was 14.1 mm in depth and 14.3 mm circumferentially. The lesion completely regressed after the delivery of 40 Gy in 20 fractions over 4 weeks. The tumor did not recur over the next year. CONCLUSION: An aggressive disease course is rare for indolent CD30+ PC-ALCL, which has similar histopathological characteristics as indolent PC-ALCL. The radiotherapy strategy should be individualized with curative intent. Lippincott Williams & Wilkins 2021-05-07 /pmc/articles/PMC8104231/ /pubmed/33950967 http://dx.doi.org/10.1097/MD.0000000000025770 Text en Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | 5700 Lyu, Wen-Tian Song, Qi-Bin Qiong, Wang Liu, Jing Yong, Ren Yi, Feng-Tao Han, Dong-liang A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma |
title | A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma |
title_full | A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma |
title_fullStr | A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma |
title_full_unstemmed | A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma |
title_short | A case report of aggressive course of CD30+ primary cutaneous anaplastic large cell lymphoma |
title_sort | case report of aggressive course of cd30+ primary cutaneous anaplastic large cell lymphoma |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104231/ https://www.ncbi.nlm.nih.gov/pubmed/33950967 http://dx.doi.org/10.1097/MD.0000000000025770 |
work_keys_str_mv | AT lyuwentian acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT songqibin acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT qiongwang acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT liujing acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT yongren acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT yifengtao acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT handongliang acasereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT lyuwentian casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT songqibin casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT qiongwang casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT liujing casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT yongren casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT yifengtao casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma AT handongliang casereportofaggressivecourseofcd30primarycutaneousanaplasticlargecelllymphoma |